Established in 1969, Kuhnil Pharmaceutical is engaged in research, development, manufacture, and sales of generic and new drug products. Since 2012, Kuhnil has been designated as ‘Innovative Pharmaceutical Company’, accredited by the Ministry of Health and Welfare of Korea. Also, Kuhnil’s manufacturing facility has received EU-Good Manufacturing Practice (EU-GMP) certification for solid dosage form manufacturing and release. Based on these competencies, we are eager to expand our presence in the overseas market including Europe, Latin America and Asia. 
Kuhnil is a fully-integrated local pharmaceutical company in Korea. Kuhnil’s pipeline is focusing on IMDs for Cardiovascular and Urology.
 

Rosumega® (Omega-3 1g + Rosuvastatin 5mg)

Rosumega® is a Fixed-dose combination drug of Rosuvastatin and omega-3 for the treatment of dyslipidemia approved in Europe and Korea.

Rosumega® can offer advantages to patients as :

  ▪ Better compliance for those who need to control not only their LCL-C but also their TC levels

  ▪ Enhanced product stability with the patented multi-player capsule coating technology

Omacor® mini capsules (Omega-3 ２g: EPA 920mg, DHA 760mg)

Omacor® seamless mini capsule is an improved version of the Omacor soft capsule. The mini-capsules are easier to swallow and come in a convenient pouch presentation which contains 2 grams of Omega-3, equivalent to 2 soft capsules. Omacor® mini capsules offer the following advantage : 

▪Better compliance for those who have difficulties from taking the relatively large size of Omacor® capsules.

Exferride® (Deferasirox Powder 125, 250, 500, 1000mg)

 Deferasirox (Original: Exjade by Novartis) is used to reduce chronic iron overload in patients who are receiving long-term blood transfusions.

With the patented technology, Kuhnil’s Exferride® can offer the following benefits:

▪Easier administration of powder formulation compared to the original’s dispersible tablet

▪More cost-effective than the original thanks to the higher dosage